Investments and Fair Value Measurements - Schedule of Changes to the Contingent liability (Details) - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2024	Mar. 31, 2023
Development and Collaboration Agreement
Beginning balance	$ 27,788
Non-cash interest expense accretion	629	$ 550
Ending balance	28,417
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Beginning balance	27,788
Non-cash interest expense accretion	629
Ending balance	$ 28,417

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration